2025-11-14T14:21:02-06:00 2024-12-31 420714325 RSM US LLP 7351 OFFICE PARK PLACE MELBOURNE FL 329408229 990 2024-01-01 231682043 AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY & THERAPEUTICS AMER 7038366981 528 NORTH WASHINGTON STREET ALEXANDRIA VA 22314 ABIGAIL W GORMAN CHIEF EXECUTIVE OFFICER 7038366981 2025-11-13 1 1 KELLI PECK P01423033 3217516200 2025-11-13 2024 2025-03-06 01:10:19Z ABIGAIL W GORMAN 528 NORTH WASHINGTON STREET ALEXANDRIA VA 22314 5281741 0 X WWW.ASCPT.ORG X 1900 DC ADVANCING CLINICAL PHARMACOLOGY, TRANSLATIONAL MEDICINE AND THERAPEUTICS FOR THE BENEFIT OF PATIENTS AND SOCIETY. SIGNIFICANT ACTIVITIES INCLUDE THREE SCHOLARLY PEER-REVIEWED JOURNALS ALONG WITH ONLINE EDUCATIONAL OPPORTUNITIES. 11 11 11 600 10904 0 58535 313183 3514192 3790108 120233 96348 7410 91750 3700370 4291389 60495 73500 0 0 1870957 1897121 0 0 0 2122107 2196023 4053559 4166644 -353189 124745 6491449 7725742 0 990157 6491449 6735585 X ADVANCING CLINICAL PHARMACOLOGY, TRANSLATIONAL MEDICINE AND THERAPEUTICS FOR THE BENEFIT OF PATIENTS AND SOCIETY. 0 0 1758472 73500 1363850 ANNUAL MEETING: THE ASCPT ANNUAL MEETING IS AN INTERNATIONAL MEETING THAT ATTRACTS PARTICIPANTS FROM AROUND THE WORLD. A SPECTRUM OF TOPICS RELATING TO THE CONTINUUM OF DRUG DISCOVERY, DEVELOPMENT, REGULATION, AND UTILIZATION ARE DISCUSSED. THE MEETING OFFERS EDUCATIONAL SESSIONS AND POSTER PRESENTATIONS, LECTURES FROM TOP PROFESSIONALS IN THE FIELD, AS WELL AS NETWORKING OPPORTUNITIES WITH CLINICAL PHARMACOLOGISTS AND TRANSLATIONAL SCIENTISTS FROM AROUND THE WORLD. 1208270 1870786 JOURNAL: CLINICAL PHARMACOLOGY AND THERAPEUTICS (CPT) IS THE AUTHORITATIVE CROSS-DISCIPLINARY JOURNAL IN EXPERIMENTAL AND CLINICAL MEDICINE DEVOTED TO PUBLISHING ADVANCES IN THE NATURE, ACTION, EFFICACY AND EVALUATION OF THERAPEUTICS. JOURNAL: CLINICAL PHARMACOLOGY & THERAPEUTICS: PHARMACOMETRICS AND SYSTEMS PHARMACOLOGY (PSP) IS A TIMELY ONLINE-ONLY CROSS-DISCIPLINARY JOURNAL PUBLISHING ADVANCES IN QUANTITATIVE METHODS AS APPLIED IN PHARMACOLOGY, PHYSIOLOGY AND THERAPEUTICS IN HUMANS. CPT HAS A 2024 IMPACT FACTOR OF 5.5. PSP HAS A 2024 IMPACT FACTOR OF 3.0.CLINICAL AND TRANSLATIONAL SCIENCE (CTS) HIGHLIGHTS ORIGINAL RESEARCH THAT HELPS BRIDGE LABORATORY DISCOVERIES WITH THE DIAGNOSIS AND TREATMENT OF HUMAN DISEASE. CTS HAS A 2024 IMPACT FACTOR OF 2.8. 675741 544568 MEMBER SERVICES: MEMBERSHIP IN ASCPT OFFERS A NUMBER OF BENEFITS WHICH DIRECTLY IMPACT ITS MEMBERS AND THEIR PROFESSIONAL DEVELOPMENT. IT PROVIDES A VARIETY OF INFORMATION AND TOOLS, SUCH AS THE CPT, PSP AND CTS JOURNALS, WEBINARS, WEBSITE AND EMAIL NEWSLETTER, EDUCATIONAL OPPORTUNITIES, SUCH AS THE ANNUAL MEETING, NETWORKING OPPORTUNITIES, AND PROFESSIONAL DEVELOPMENT OPPORTUNITIES. 3642483 1 1 0 1 0 0 0 0 0 0 1 1 0 0 1 1 0 0 0 0 1 0 1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 46 0 1 11 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 11 11 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA CO CT FL GA IL KS MA MD MO NC NJ NY PA TN TX VA WA WI HI WY X THE SOCIETY 7038366981 528 NORTH WASHINGTON STREET ALEXANDRIA VA 22314 MATTHEW RIZK PHD PRESIDENT 4.00 X X 0 0 0 WALTER KRAFT MD IMMEDIATE PAST PRESIDENT 4.00 X X 0 0 0 MARK DRESSER PHD IMMEDIATE PAST PRES. (UNTIL 3/2024) 4.00 X X 0 0 0 SANDRA VISSER PHD PRESIDENT-ELECT 4.00 X X 0 0 0 JACQUES TURGEON TREASURER 4.00 X X 0 0 0 ANTOINETTE AJAVON-HARTMANN PHD DIRECTOR 4.00 X 0 0 0 LISA BENINCOSA PHD DIRECTOR 4.00 X 0 0 0 SHAYNA KILLAM PHARMD DIRECTOR 4.00 X 0 0 0 JING LIU PHD DIRECTOR 4.00 X 0 0 0 KATHRYN MOMARY PHARMD DIRECTOR 4.00 X 0 0 0 DANIELE OUELLET PHD DIRECTOR (UNTIL 4/2024) 4.00 X 0 0 0 LUANA PESCO-KOPLOWITZ MD PHD DIRECTOR (UNTIL 4/2024) 4.00 X 0 0 0 ANU RAMAMOORTHY PHD DIRECTOR 4.00 X 0 0 0 STEPHANI STANCIL PHD DIRECTOR 4.00 X 0 0 0 ABIGAIL GORMAN CHIEF EXECUTIVE OFFICER 40.00 X 410130 0 84562 ELISE LAFFMAN-JOHNSON CHIEF OPERATING OFFICER 40.00 X 240960 0 29819 LISA INFELISE SR DIR, MBR SVCS 40.00 X 149328 0 26660 ALETHEA GERDING MANAGING EDITOR 40.00 X 126347 0 16036 926765 0 157077 4 0 1 0 RSM US LLP 331 WEST 3RD STREET SUITE 200 DAVENPORT IA 52801 ACCOUNTING SERVICES 120295 1 313183 313183 JOURNALS 900099 1881690 1870786 10904 ANNUAL MEETING 900099 1363850 1363850 MEMBERSHIP DUES 900099 544568 544568 3790108 104535 104535 982165 990352 -8187 -8187 -8187 MISCELLANEOUS 900099 91750 91750 91750 4291389 3779204 10904 188098 10000 10000 49500 49500 14000 14000 765472 615773 149699 906364 729112 177252 77195 77195 50554 50554 97536 87527 10009 25727 25727 134382 134382 21424 21424 203087 88952 114135 209351 108972 100379 753 753 22124 22124 97988 82727 15261 1055823 1038816 17007 171 171 83690 83690 62469 26302 36167 OUTSIDE SERVICES 228834 228834 MEMBERSHIP SERVICES 50200 50200 OVERHEAD ALLOCATION 0 511768 -511768 4166644 3642483 524161 0 849068 394690 1057553 317061 2231025 810172 1477742 1420853 2015987 2236658 1773132 1942984 375520 353645 0 2298 6491449 7725742 308439 679372 0 2346 0 990157 X 5900452 5753203 590997 982382 6491449 6735585 6491449 7725742 X 124745 366225 -246834 X X 0 1 X 1 0 X 267198 252731 88469 58535 313183 980116 1699602 3947101 3454758 3510673 3779204 16391338 1966800 4199832 3543227 3569208 4092387 17371454 12582 23005 31770 25728 15928 109013 1298688 1497013 1498914 1352909 1561835 7209359 1311270 1520018 1530684 1378637 1577763 7318372 10053082 74286 88823 63603 107874 104535 439121 74286 88823 63603 107874 104535 439121 5131 906 3815 7410 91750 109012 2046217 4289561 3610645 3684492 4288672 17919587 0.56100 0.58130 0.02450 0.02460 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: INCOME FROM ACTIVITIES NOT NORMALLY RECURRING RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 4145223 4145223 357261 89315 0 0 313401 311755 351733 357261 1334150 2001225 78350 77939 87933 89315 333537 500306 186000 186000 1837218 609544 1227674 26081 18902 7179 181726 181726 0 1420853 ISHARES CORE S&P 500 1431670 C US TREASURY 511314 C 1942984 LEASE LIABILITY 2346 2346 X PART X, LINE 2: THE SOCIETY IS GENERALLY EXEMPT FROM FEDERAL INCOME TAXES UNDER THE PROVISIONS OF SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. IN ADDITION, THE SOCIETY HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 509(A) OF THE INTERNAL REVENUE CODE. THE SOCIETY IS EXEMPT FROM TAXES ON INCOME OTHER THAN UNRELATED BUSINESS INCOME. NO TAX LIABILITY FOR UNRELATED BUSINESS INCOME HAS BEEN ACCRUED AS OF DECEMBER 31, 2024, AS THE SOCIETY DID NOT EARN SIGNIFICANT NET UNRELATED BUSINESS INCOME. AS OF DECEMBER 31, 2024, THE STATUTE OF LIMITATIONS REMAINED OPEN FOR THE U.S. JURISDICTIONS IN WHICH THE SOCIETY FILES TAX RETURNS; HOWEVER, THERE ARE CURRENTLY NO EXAMINATIONS PENDING OR IN PROGRESS. IT IS THE SOCIETY'S POLICY TO RECOGNIZE INTEREST AND/OR PENALTIES RELATED TO UNCERTAINTY IN INCOME TAXES, IF ANY, IN INCOME TAX OR INTEREST EXPENSE. AS OF DECEMBER 31, 2024, THE SOCIETY HAD NO ACCRUALS FOR INTEREST AND/OR PENALTIES. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 1000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 5500 SOUTH AMERICA 0 0 GRANTMAKING 7500 0 0 0 0 0 0 14000 0 14000 STUDENT/TRAINEE TRAVEL GRANT EAST ASIA AND THE PACIFIC 2 1000 WIRE LMIC TRAVEL GRANT SOUTH AMERICA 1 7500 WIRE STUDENT/TRAINEE TRAVEL GRANT EUROPE (INCLUDING ICELAND & GREENLAND) 1 500 ELECTRONIC PAYMENT DOLORES SHOCKLEY IN CLINICAL RESEARCH AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1000 ELECTRONIC PAYMENT GARY NEIL PRIZE FOR INNOVATION IN DRUG DEVELOPMENT EUROPE (INCLUDING ICELAND & GREENLAND) 1 2500 WIRE SHEINER-BEAL AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1500 DONATED 0 0 0 0 0 0 PART I, LINE 2: EACH YEAR ASCPT'S AWARDS PROGRAM PROVIDES AN ARRAY OF AWARDS THAT RECOGNIZE OUTSTANDING SCIENCE AND ACHIEVEMENT IN CLINICAL PHARMACOLOGY AND TRANSLATIONAL SCIENCE. ASCPT'S AWARDS SPAN THE CONTINUUM OF CLINICAL PHARMACOLOGY, TRANSLATIONAL MEDICINE, AND THERAPEUTICS. THE ARRAY OF AWARDS IS DESIGNED TO RECOGNIZE EVERY TURNING POINT IN THE CAREER PATH FROM YOUNG INVESTIGATOR TO SEASONED SCIENTIST WITH THE FOCUS ON EXCEPTIONAL ACHIEVEMENTS IN THE DIMENSIONS THAT THE AWARDS ARE FOCUSED. EACH AWARD CANDIDATE IS NOMINATED THROUGH THE SUBMISSION OF A NOMINATION PACKET THAT INCLUDES A SUMMARIZED CV AND COMPREHENSIVE ASSESSMENT OF ALL ASPECTS OF THE CANDIDATES OUTSTANDING ATTRIBUTES. ADDITIONALLY, 1 TO 3 RECOMMENDATIONS MUST BE INCLUDED FROM INDIVIDUALS AS WELL AS THE CANDIDATE'S COMPLETE CV AND HIGHLIGHTS OF NOTEWORTHY SCIENTIFIC ACCOMPLISHMENTS. AFTER THE SELECTION PROCESS IS COMPLETE, THE RECIPIENTS RECEIVE THE MONETARY AWARD, A TRAVEL STIPEND TO THE ANNUAL MEETING AND RECOGNITION DURING THE ANNUAL MEETING. 1 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 855 FOLSOM STREET STE 425 SAN FRANCISCO CA 94143 946036493 501 (C)(3) 10000 0 DARRELL ABERNETHY EARLY INVESTIGATOR AWARD 1 0 STUDENT/TRAINEE TRAVEL GRANT 53 26500 PRESIDENTIAL TRAINEE AWARD 26 13000 LEON GOLDBERG EARLY INVESTIGATOR AWARD 1 1000 WILLIAM B. ABRAMS AWARD 1 1000 RAWLS-PALMER PROGRESS IN MEDICINE AWARD 1 1000 FDA/ASCPT ABRAMS AWARD 1 500 PRESIDENTIAL TRAINEE/ MORROW AWARD 1 1500 OSCAR B. HUNTER CAREER AWARD IN THERAPEUTICS 1 1500 MALLE JURIMA-MALLE MID-CAREER LEADERSHIP AWARD 1 1000 PRESIDENTIAL TRAINEE/ GOLDSTEIN AWARD 1 1500 HENRY W. ELLIOTT DISTINGUISHED SERVICE AWARD 1 1000 PART I, LINE 2: EACH YEAR ASCPT'S AWARDS PROGRAM PROVIDES AN ARRAY OF AWARDS THAT RECOGNIZE OUTSTANDING SCIENCE AND ACHIEVEMENT IN CLINICAL PHARMACOLOGY AND TRANSLATIONAL SCIENCE. ASCPT'S AWARDS SPAN THE CONTINUUM OF CLINICAL PHARMACOLOGY, TRANSLATIONAL MEDICINE, AND THERAPEUTICS. THE ARRAY OF AWARDS IS DESIGNED TO RECOGNIZE EVERY TURNING POINT IN THE CAREER PATH FROM YOUNG INVESTIGATOR TO SEASONED SCIENTIST WITH THE FOCUS ON EXCEPTIONAL ACHIEVEMENTS IN THE DIMENSIONS THAT THE AWARDS ARE FOCUSED. EACH AWARD CANDIDATE IS NOMINATED THROUGH THE SUBMISSION OF A NOMINATION PACKET THAT INCLUDES A SUMMARIZED CV AND COMPREHENSIVE ASSESSMENT OF ALL ASPECTS OF THE CANDIDATE'S OUTSTANDING ATTRIBUTES. ADDITIONALLY, 1 TO 3 RECOMMENDATIONS MUST BE INCLUDED FROM INDIVIDUALS AS WELL AS THE CANDIDATE'S COMPLETE CV AND HIGHLIGHTS OF NOTEWORTHY SCIENTIFIC ACCOMPLISHMENTS. AFTER THE SELECTION PROCESS IS COMPLETE, THE RECIPIENTS RECEIVE A TRAVEL STIPEND TO THE ANNUAL MEETING AND RECOGNITION DURING THE ANNUAL MEETING. A MONETARY AWARD IS PRESENTED AFTER THE ANNUAL MEETING. X X X X 0 0 0 0 0 0 0 0 0 ABIGAIL GORMAN CHIEF EXECUTIVE OFFICER 372630 0 37500 0 0 0 36300 0 48262 0 494692 0 0 0 ELISE LAFFMAN-JOHNSON CHIEF OPERATING OFFICER 240960 0 0 0 0 0 28234 0 1585 0 270779 0 0 0 LISA INFELISE SR DIR, MBR SVCS 149328 0 0 0 0 0 17490 0 9170 0 175988 0 0 0 PART I, LINE 7 THE PROCESS FOR CALCULATING THE STAFF BONUS IS DEPENDENT ON PERFORMANCE AND DISCUSSIONS WITH THE COMPENSATION COMMITTEE AND THE CEO. THE CEO'S BONUS IS CALCULATED BASED ON ACHIEVEMENT OF INCENTIVE OBJECTIVES THAT ARE APPROVED BY THE COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION A, LINE 6 THE SOCIETY HAS FOUR CLASSES OF MEMBERS: FULL MEMBER, EARLY CAREER MEMBER, EMERITUS MEMBER, AND TRAINEE/STUDENT MEMBER. FULL MEMBER: FOR APPLICANTS WHO HAVE EARNED A DOCTORATE DEGREE OR EQUIVALENT IN ANY OF THE BIOMEDICAL SCIENCES. ALSO FOR APPLICANTS IN EXECUTIVE AND LEADERSHIP ROLES IN RELATED ORGANIZATIONS. APPLICANTS MUST DEMONSTRATE A SINCERE INTEREST IN, AND CONTRIBUTIONS TO, HUMAN PHARMACOLOGY AND THERAPEUTICS THROUGH PUBLICATIONS, GRANTS, PATENTS, GOVERNMENTAL REPORTS, COMPANY REPORTS, ETC. EARLY CAREER MEMBER: AN EARLY CAREER MEMBER IS A SCIENTIST IN THEIR FIRST SEVEN YEARS OF PRACTICE. EMERITUS MEMBER: EMERITUS MEMBERS HAVE COMPLETED AT LEAST 20 YEARS OF MEMBERSHIP AND HAVE REACHED THE AGE OF 65. TRAINEE/STUDENT MEMBER: FOR APPLICANTS CURRENTLY ENROLLED IN A POST-DOCTORAL TRAINING PROGRAM WHO HAVE DEMONSTRATED AN INTEREST IN HUMAN PHARMACOLOGY AND THERAPEUTICS. ALSO FOR APPLICANTS WHO ARE PURSUING A POST-BACCALAUREATE DEGREE AND WHO POSSESS AN INTEREST IN HUMAN PHARMACOLOGY AND THERAPEUTICS. FORM 990, PART VI, SECTION A, LINE 7A MEMBERS SHALL HAVE SUCH VOTING PRIVILEGES AS ARE DETERMINED FROM TIME TO TIME BY THE SOCIETY'S GOVERNING BOARD AND SHALL VOTE IN SUCH MANNER AS DETERMINED BY THE GOVERNING BOARD. FORM 990, PART VI, SECTION A, LINE 7B ANY CHANGES TO THE ORGANIZATION'S BYLAWS ARE SUBJECT TO APPROVAL BY THE FULL MEMBERS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS REVIEWED BY ALL MEMBERS OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ALL ASCPT VOLUNTEER LEADERS COMPLETE A WRITTEN CONFLICT OF INTEREST DISCLOSURE. THE CEO, LEGAL COUNSEL, AND SENIOR STAFF ARE AWARE OF CONFLICTS, AND DISCUSS ANY ACTUAL OR POTENTIAL COI ISSUES. CONFLICT OF INTEREST IS DISCUSSED AT THE BEGINNING OF EVERY BOARD OF DIRECTORS CONFERENCE CALL, WITH BOARD MEMBERS BEING ASKED TO DECLARE ANY CONFLICTS AT THE BEGINNING OF THE CALL. MONITORING AND COMPLIANCE WAS DONE WITH THE ORGANIZATIONAL STAFF MEMBERS AND LEGAL COUNSEL. FORM 990, PART VI, SECTION B, LINE 15 THE ASCPT COMPENSATION COMMITTEE REVIEWS AND APPROVES THE CEO SALARY WITH COMPARABILITY DATA AND CONTEMPORANEOUS SUBSTANTIATION OF THE DECISION. THE CEO REVIEWS OTHER KEY EMPLOYEES USING COMPARABILITY DATA AND CONTEMPORANEOUS SUBSTANTIATION OF THE DECISION. DECISIONS OF THE BOARD ARE GUIDED BY A CAREFULLY ESTABLISHED AND DISCUSSED STRATEGIC PLAN. THE PLAN IS KNOWN TO THE MEMBERS AND PROGRESS IS DISCLOSED. KEY EMPLOYEES ARE EXPECTED TO MANAGE AND OPERATE ACCORDING TO THE BOARD GUIDANCE AND IN LINE WITH THE ELEMENTS OF THE STRATEGIC PLAN. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE ON THE ASCPT WEBSITE. FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST FOR THE PERIOD AS SET FORTH IN IRC SECTION 6104(D). FORM 990, PART XI, LINE 9: CASH TO ACCRUAL BASIS ADJUSTMENT -246,834. FORM 990, PART XII, LINE 2C: THE OVERSIGHT AND SELECTION PROCESS HAS NOT CHANGED FROM THE PRIOR TAX YEAR.